GC
TTPH

Guggenheim Capital’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Guggenheim Capital’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,335
Closed -$306K – 3291
2013
Q3 		$306K Sell
1,335
-583
-30% -$102K ﹤0.01% 2601
2013
Q2 		$270K Buy
+1,918
New +$304K ﹤0.01% 2650

Other funds holding TTPH

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return

Guggenheim Capital's TTPH Position: Q4 2013 in Review

Guggenheim Capital sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2013, closing a stake of 1,335 shares — an estimated $306K sold.

Guggenheim Capital first reported a position in TTPH in Q2 2013 and held it in 2 quarters. The position peaked at $306K in Q3 2013. 54 funds tracked by Wall St. Rank hold TTPH as of Q4 2013.

  • Guggenheim Capital reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Guggenheim Capital sold 1,335 Tetraphase Pharmaceuticals, Inc. shares in Q4 2013, an estimated $306K.
  • Guggenheim Capital first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Guggenheim Capital's Tetraphase Pharmaceuticals, Inc. position peaked at $306K in Q3 2013.
  • 54 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2013.

Based on Guggenheim Capital's 13F filing for Q4 2013, filed 14 Feb 2014.